Evidence map›Paper›PMID 25461801›Full record

Trial reportBritish journal of cancer2015

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test.

O Otero-Estévez, L De Chiara, F J Rodríguez-Berrocal, M Páez de la Cadena, J Cubiella, I Castro, C Gonzalez-Mao, V Hernandez, V S Martínez-Zorzano

Open access · hybridAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Future of Colorectal Cancer Screening: From One-Size-FITs-All to Tailor-Made.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Familial colorectal cancer screening: When and what to do?World journal of gastroenterology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

O Otero-EstévezDepartment of Biochemistry, Genetics and Immunology, Universidad de Vigo, 36310 Vigo, Spain.
L De ChiaraDepartment of Biochemistry, Genetics and Immunology, Universidad de Vigo, 36310 Vigo, Spain.
F J Rodríguez-BerrocalDepartment of Biochemistry, Genetics and Immunology, Universidad de Vigo, 36310 Vigo, Spain.
M Páez de la CadenaDepartment of Biochemistry, Genetics and Immunology, Universidad de Vigo, 36310 Vigo, Spain.
J CubiellaDepartment of Gastroenterology, Complexo Hospitalario Universitario de Ourense, 32005 Ourense, Spain.
I CastroDepartment of Gastroenterology, Complexo Hospitalario Universitario de Ourense, 32005 Ourense, Spain.
C Gonzalez-MaoDepartment of Clinical Analysis, Complexo Hospitalario Universitario de Vigo, 36200 Vigo, Spain.
V HernandezDepartment of Gastroenterology, Complexo Hospitalario Universitario de Vigo, 36200 Vigo, Spain.
V S Martínez-ZorzanoDepartment of Biochemistry, Genetics and Immunology, Universidad de Vigo, 36310 Vigo, Spain.
Universidade de Vigo · ESComplejo Hospitalario de Ourense · ESComplexo Hospitalario Universitario A Coruña · ESUniversity Hospital Complex Of Vigo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of specific screening programs for individuals with a family history of colorectal cancer (CRC) is a priority. This study evaluates the diagnostic performance of serum soluble CD26 (sCD26) in family-risk individuals and compares this marker with the faecal immunochemical test for the detection of advanced neoplasia (AN) (CRC or advanced adenomas; AA).

methodsFive hundred and sixteen asymptomatic individuals with at least one first-degree relative with CRC were included. Serum sCD26 was measured in all the individuals who also underwent a colonoscopy (53 AA and four cancer cases were found) and a faecal immunochemical test.

resultsSetting specificity to 90% and 95%, respectively, sCD26 showed a sensitivity of 39.6% and 28.3% for AA, and of 42.1% and 28.1% for AN. The combination of sCD26 and the faecal test detected AA and AN with a 52.8% and 56.1% sensitivity, corresponding to 93.5% specificity.

conclusionsThe combination of serum sCD26 and the faecal blood test could result a valuable strategy for detecting AN in familial-risk CRC screening.

Indexed as

Occult BloodAdenomaAdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsDipeptidyl Peptidase 4Double-Blind MethodEarly Detection of CancerFemaleHumansImmunoassayMaleMiddle AgedProspective StudiesBiomarkers, TumorDipeptidyl Peptidase 4DPP4 protein, human

Identifiers

PMID25461801
PMCPMC4453459
OpenAlexW1979691624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.